FibroBiologics Statistics
Total Valuation
FibroBiologics has a market cap or net worth of $7.06 million. The enterprise value is $5.00 million.
| Market Cap | 7.06M |
| Enterprise Value | 5.00M |
Important Dates
The last earnings date was Friday, July 31, 2026, after market close.
| Earnings Date | Jul 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
FibroBiologics has 6.66 million shares outstanding. The number of shares has increased by 112.97% in one year.
| Current Share Class | 6.66M |
| Shares Outstanding | 6.66M |
| Shares Change (YoY) | +112.97% |
| Shares Change (QoQ) | +66.25% |
| Owned by Insiders (%) | 4.80% |
| Owned by Institutions (%) | 7.05% |
| Float | 6.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.64 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -77.81 |
Financial Efficiency
Return on equity (ROE) is -660.08% and return on invested capital (ROIC) is -117.92%.
| Return on Equity (ROE) | -660.08% |
| Return on Assets (ROA) | -95.77% |
| Return on Invested Capital (ROIC) | -117.92% |
| Return on Capital Employed (ROCE) | -292.67% |
| Weighted Average Cost of Capital (WACC) | 11.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.00% in the last 52 weeks. The beta is 1.22, so FibroBiologics's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | -91.00% |
| 50-Day Moving Average | 0.86 |
| 200-Day Moving Average | 3.69 |
| Relative Strength Index (RSI) | 62.18 |
| Average Volume (20 Days) | 166,917 |
Short Selling Information
The latest short interest is 115,200, so 1.73% of the outstanding shares have been sold short.
| Short Interest | 115,200 |
| Short Previous Month | 70,837 |
| Short % of Shares Out | 1.73% |
| Short % of Float | 1.92% |
| Short Ratio (days to cover) | 1.34 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.73M |
| Pretax Income | -18.14M |
| Net Income | -18.14M |
| EBITDA | -16.47M |
| EBIT | -16.73M |
| Earnings Per Share (EPS) | -$4.77 |
Balance Sheet
The company has $3.52 million in cash and $1.46 million in debt, with a net cash position of $2.05 million or $0.31 per share.
| Cash & Cash Equivalents | 3.52M |
| Total Debt | 1.46M |
| Net Cash | 2.05M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 4.64M |
| Book Value Per Share | 0.76 |
| Working Capital | 3.64M |
Cash Flow
In the last 12 months, operating cash flow was -$14.79 million and capital expenditures -$6,000, giving a free cash flow of -$14.80 million.
| Operating Cash Flow | -14.79M |
| Capital Expenditures | -6,000 |
| Depreciation & Amortization | 263,000 |
| Net Borrowing | -3.28M |
| Free Cash Flow | -14.80M |
| FCF Per Share | -$2.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FibroBiologics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -112.97% |
| Shareholder Yield | -112.97% |
| Earnings Yield | -257.01% |
| FCF Yield | -209.64% |
Analyst Forecast
The average price target for FibroBiologics is $12.50, which is 1,079.25% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.50 |
| Price Target Difference | 1,079.25% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on March 30, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Mar 30, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |